Auweiler, Philipp; Müller, Dirk; Stock, Stephanie; … - In: PharmacoEconomics 30 (2012) 7, pp. 537-549
Adding rituximab to standard chemotherapy is considered a cost-effective treatment option for NHL. However, the results of the analyses should be interpreted with caution due to methodological limitations. </AbstractSection> Copyright Springer International Publishing AG 2012
